Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in by Blann A

Get full text

ABC of antithrombotic therapy: An overview of antithrombotic therapy. by Blann, A, Landray, M, Lip, G

Oxidative stress in malignant and non-malignant phase hypertension. by Lip, G, Edmunds, E, Nuttall, S, Landray, M, Blann, A, Beevers, D

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. by Deplanque, G, Madhusudan, S, Jones, P, Wellmann, S, Christodoulos, K, Talbot, D, Ganesan, T, Blann, A, Harris, A

Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. by Landray, M, Wheeler, D, Lip, G, Newman, D, Blann, A, McGlynn, F, Ball, S, Townend, J, Baigent, C

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer by Khan, O, Blann, A, Payne, M, Middleton, MR, Protheroe, A, Talbot, D, Taylor, M, Han, C, Patil, M, Harris, A

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate by Khan, O, Blann, A, Payne, M, Middleton, MR, Protheroe, A, Talbot, D, Taylor, M, Han, C, Patil, M, Harris, A

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate. by Khan, O, Blann, A, Payne, M, Middleton, MR, Protheroe, A, Talbot, D, Taylor, M, Han, C, Patil, M, Harris, A

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. by Khan, O, Blann, A, Payne, M, Middleton, MR, Protheroe, A, Talbot, D, Taylor, M, Kirichek, O, Han, C, Patil, M, Harris, A